Edition:
United States

People: Evogene Ltd (EVGN.OQ)

EVGN.OQ on NASDAQ Stock Exchange Global Market

2.87USD
21 May 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.87
Open
$2.88
Day's High
$2.88
Day's Low
$2.88
Volume
80
Avg. Vol
2,738
52-wk High
$5.76
52-wk Low
$2.66

Gerstel, Martin 

Mr. Martin Gerstl serves as Chairman of the Board at Evogene Ltd. since 2004. He serves as Chairman of Compugen Ltd., a drug and diagnostic discovery company, of Keddem Bioscience, a drug discovery company and he also serves as Co-Chairman of Itamar Medical, a medical device company, all of which are headquartered in Israel. Prior to relocating to Israel in 1994, Mr. Gerstel was the Co-Chairman and CEO of ALZA Corporation, a pharmaceutical company based on advanced drug delivery. In addition, Mr. Gerstel currently serves as a Director of YEDA Technology Transfer, Yissum Technologies and the Foundation for the US National Medals of Science and Technology. He is a member of the Board of Governors and the Executive Committee of the Weizmann Institute of Science and the Board of Governors of the Hebrew University of Jerusalem, and is an advisor to the Burrill Life Science Funds and to the Board of the Israel-U.S. BiNational Industrial Research and Development (BIRD) Foundation. Mr. Gerstel holds a BSC degree in Science from the Yale University and an MBA degree from the Stanford University.

Basic Compensation

Total Annual Compensation, ILS --
Restricted Stock Awards, ILS 56,000
Long-Term Incentive Plans, ILS --
All Other, ILS --
Fiscal Year Total, ILS 56,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --